In vitro preclinical studies show high potency of pyrotinib, comparable to neratinib, against HER2 dependent BT474 (breast cancer) and SK-OV-3 (ovarian cancer) cell lines and also in vivo efficacy in HER2-dependent mouse xenograft models. This evidence concerns the gene ERBB2 and ovarian carcinoma.